New hope for rare nerve disease: phase 3 trial of nucresiran begins
NCT ID NCT07223203
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 26 times
Summary
This study tests a new medicine, nucresiran, for people with a rare inherited disease that damages nerves (hATTR-PN). About 125 adults will receive either nucresiran or another drug (vutrisiran) to see which better slows nerve damage and improves quality of life. The goal is to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
RECRUITINGBaltimore, Maryland, 21287, United States
-
Clinical Trial Site
RECRUITINGBoston, Massachusetts, 02118, United States
-
Clinical Trial Site
RECRUITINGDallas, Texas, 75246, United States
-
Clinical Trial Site
RECRUITINGSão Paulo, 04038-002, Brazil
-
Clinical Trial Site
RECRUITINGLe Kremlin-Bicêtre, 94270, France
-
Clinical Trial Site
RECRUITINGFlorence, 50134, Italy
-
Clinical Trial Site
RECRUITINGMilan, 20133, Italy
-
Clinical Trial Site
RECRUITINGSuita, 565-0871, Japan
-
Clinical Trial Site
RECRUITINGKuala Lumpur, 59100, Malaysia
-
Clinical Trial Site
NOT_YET_RECRUITINGPorto, 4099-001, Portugal
-
Clinical Trial Site
RECRUITINGSeoul, 05030, South Korea
-
Clinical Trial Site
RECRUITINGSeoul, 06351, South Korea
-
Clinical Trial Site
RECRUITINGStockholm, 113 61, Sweden
-
Clinical Trial Site
RECRUITINGUmeå, 907 37, Sweden
-
Clinical Trial Site
NOT_YET_RECRUITINGTaipei, 112, Taiwan
-
Clinical Trial Site
RECRUITINGTaoyuan City, 333, Taiwan
Conditions
Explore the condition pages connected to this study.